InflaRx N.V. (IFRX) Live Share Price, Invest From India

InflaRx N.V. Stock Performance

as on June 24, 2026 at 6:59 am IST

Day's Low
Day's High
$1.84
Day's Price Range
$1.98
$1.93
4.66%
Downside
2.59%
Upside
52 Week's Low
52 Week's High
$0.74
52-Week Price Range
$2.95
$1.93
61.63%
Downside
52.79%
Upside

InflaRx N.V. share price movements today

Previous Close: $1.90
Open: $1.84
Volume: 872.0K
Day's Low - High: $1.84 - $1.98
52 Week Low - High: $0.74 - $2.95

InflaRx N.V. Historical Returns

1 Month Return: -27.2 %
3 Month Return: + 96.3 %
1 Year Return: + 139.6 %
3 Year Return: -58.42 %
5 Year Return: -36.67 %

InflaRx N.V. Stock Fundamentals & Key Indicators

Check InflaRx N.V. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$278.4M

EPS (TTM)

-0.3

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

PEG Ratio

EBITDA

-42.4M

Revenue (TTM)

29.3K

Profit Margin

0.00%

Return On Equity TTM

-79.94%

InflaRx N.V. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of InflaRx N.V. with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %	Dividend Yield %
InflaRx N.V.	BUY	$278.4M	-36.67%	NA	0.00%	NA
Alnylam Pharmaceuticals Inc.	BUY	$37.1B	64.01%	69.87	12.55%	NA
Vertex Pharmaceuticals Inc.	BUY	$114.6B	148.93%	26.8	35.51%	NA
Regeneron Pharmaceuticals Inc.	BUY	$63.9B	15.61%	14.88	29.65%	0.59%

Stock Returns calculator for InflaRx N.V. Stock including INR - Dollar returns

The InflaRx N.V. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

InflaRx N.V. investment value today

Current value as on today

₹2,67,315

Returns

₹1,67,315

(+167.31%)

Returns from InflaRx N.V. Stock

₹1,44,304 (+144.3%)

Dollar Impact

₹23,011 (+23.01%)

Analyst Recommendation on InflaRx N.V. Stock

Based on 11 analysts

BUY

81.82%

Buy

18.18%

Hold

0.00%

Sell

Based on 11 analysts, 81.82% of analysts recommend a 'BUY' rating for InflaRx N.V.. Average target price of $7.79

InflaRx N.V. Share Price Target

Get share price movements and forecasts by analysts on InflaRx N.V..

What analysts predicted

75.22%UPSIDE

Target Price

$7.79

Current Price

$1.93

Analyzed by

11 Analysts

Target

$7.79

InflaRx N.V. target price $7.79, a slight upside of 75.22% compared to current price of $1.93. According to 11 analysts rating.

Indian Investors' Interest in InflaRx N.V. Stock

Search interest for InflaRx N.V. Stock has decreased by -49% in the last 30 days, reflecting a downward trend in search activity.

Time period: May 25, 2026 to June 24, 2026

Change:-49% versus previous 30 day period

InflaRx N.V. Quarterly Profit & Loss

All numbers in Millions USD

	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Total Revenue	0	0	0	0	0	-	0	0	0	-
Gross Profit	0	0	0	0	-2	0	-2	0	-4	0
Operating Income	-13	-12	-15	-15	-9	-13	-12	-9	-12	-7
EBITDA	-15	-9	-12	-17	-4	-8	-14	-12	-10	-5
Interest Expense	0	0	0	0	0	0	0	0	0	0
Depreciation	0	0	0	0	0	0	0	0	0	0
Income Before Tax	-15	-9	-12	-17	-5	-8	-14	-12	-10	-5
Income Tax Expense	0	0	0	0	-	-	-	0	0	-
Net Income	-17	-9	-13	-17	-5	-8	-14	-12	-10	-5
Net Profit Margin	-696857.22%	-26798.11%	-217803.07%	-14092.87%	1208456.74%	0.00%	-36559.83%	-51452.32%	31364.81%	0.00%

InflaRx N.V. Annual Profit & Loss

All numbers in Millions USD

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Revenue	-	0	-	-	-	-	-	0	0	0
Gross Profit	0	0	0	0	0	0	0	0	-3	-7
Operating Income	-6	-19	-37	-56	-33	-47	-32	-44	-52	-48
EBITDA	-7	-19	-37	-56	-33	-44	-28	-42	-45	-45
Interest Expense	1	2	-	0	0	0	0	0	0	0
Depreciation	-	0	0	0	0	0	0	0	0	0
Income Before Tax	-8	-24	-29	-53	-33	-45	-29	-42	-46	-45
Income Tax Expense	1	2	7	-3	0	0	-2	0	0	0
Net Income	-9	-28	-33	-59	-41	-51	-31	-46	-48	-45
Net Profit Margin	0.00%	-10492.64%	0.00%	0.00%	0.00%	0.00%	0.00%	-67630.69%	-27784.96%	-155582.08%

InflaRx N.V. Quarterly Cash Flow

All numbers in Millions USD

	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Net Income	-9	-13	-17	-5	-8	-14	-12	-8	-5
Operating Cash Flow	-14	-12	-9	-11	-14	-7	-9	-4	-7
Investing Cash Flow	26	5	17	1	17	-24	2	7	6
Financing Cash Flow	0	0	0	0	27	0	0	6	0
Change in Cash	12	-5	7	-7	28	-34	-6	9	8

InflaRx N.V. Annual Cash Flow

All numbers in Millions USD

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Net Income	-24	-29	-53	-33	-45	-29	-42	-46	-43
Operating Cash Flow	-12	-23	-43	-36	-39	-33	-37	-48	-33
Investing Cash Flow	0	-99	20	21	-25	19	-17	52	3
Financing Cash Flow	108	49	0	9	61	1	52	0	32
Change in Cash	94	-67	-22	-7	0	-9	-3	5	0

Global Institutional Holdings in InflaRx N.V.

Funds	Holdings
Marshall Wace Asset Management Ltd	0.38%
RA Capital Management, LLC	2.91%
DCF Advisers, LLC	0.11%
UBS O'Connor LLC	0.22%
GSA Capital Partners LLP	0.09%

See all

Insights on InflaRx N.V.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Best in 1 Year
In the last 1 year, IFRX has outperformed top 5 stocks with highest market-cap in its industry
POSITIVE IMPACT
Price Rise
In the last 7 days, IFRX stock has moved up by 18.7%
NO EFFECT
Against Peers
In the last 3 years, InflaRx N.V. Common Stock has experienced a drawdown of -58.4%, however Alnylam Pharmaceuticals, Inc. Common Stock resisted the overall trend and outperformed by 37.0%

About InflaRx N.V.

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a a first-in-class monoclonal anti-human complement factor C5a antibody, which is in Phase 3 clinical trial for the treatment for patients suffering from early septic organ dysfunction, biological proof of concept was established, demonstrating its unique C5a blocking ability and selectivity; Izicopan, an oral, low molecular weight drug to target C5aR with high affinity and selectivity has completed completing Phase 2a trials; and IFX002, an advancement of vilobelimab technology, which is in preclinical development for the treatment of chronic inflammatory indications. It has co-development agreement with Staidson (Beijing) BioPharmaceuticals Co., Ltd.; Cell line sales agreement with Catalent Pharma Solutions LLC; Clinical Trial Collaboration Agreement with the U.S. DHHSs, Administration for Strategic Preparedness and Response (ASPR), BARDA and PPD Development, L.P., or PPD. InflaRx N.V. was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. The company was founded in 2007 and is headquartered in Jena, Germany.

Organisation	InflaRx N.V.
Headquarters	Winzerlaer Str. 2, Jena, Germany, 07745
Industry	Biotechnology
CEO	Prof. Niels C. Riedemann M.D., Ph.D.
E-voting on shares	Click here to vote

Key Management of InflaRx N.V.

Name	Title
Prof. Niels C. Riedemann M.D., Ph.D.	Co-Founder, CEO & Executive Director
Ms. Derval O'Carroll	Senior VP and Global Head of Regulatory Affairs & Compliance
Dr. Camilla Chong M.D.	Chief Medical Officer
Mr. Kofi Boaten	VP and Head of Supply Quality & Clinical Trial Supplies
Dr. Maria Habel PH.D.	VP, Head of Preclinical R&D and QC
Mr. Peter Hurt Ph.D.	Senior Director and Head of Drug Safety & Pharmacovigiliance
Prof. Renfeng Guo M.D.	Co-Founder, Chief Scientific Officer & Executive Director
Dr. Thomas Taapken Ph.D.	Chief Financial Officer
Mr. Jan Medina CFA	Head of Investor Relations & VP
Mr. Christian Schmid	VP and Head of Legal Affairs & General Counsel

FAQs

What is InflaRx N.V. share price today?

InflaRx N.V. share price today is $1.93 as on June 24, 2026 at 1:29 am IST at the close of the market. InflaRx N.V. share today touched a day high of $1.98 and a low of $1.84.

What is the 52 week high and 52 week low for InflaRx N.V. share?

InflaRx N.V. share touched a 52 week high of $2.95 on May 7, 2026 and a 52 week low of $0.74 on August 7, 2025. InflaRx N.V. stock price today i.e. June 24, 2026 at 1:29 am IST is closed at $1.93,which is 34.55% down from its 52 week high and 160.60% up from its 52 week low.

What is InflaRx N.V.'s market capitalisation today?

InflaRx N.V. market capitalisation is $0.00T as on June 24, 2026 at 1:29 am IST.

How to invest in InflaRx N.V. Stock (IFRX) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for InflaRx N.V. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in InflaRx N.V. Shares that will get you 0.7772 shares as per InflaRx N.V. share price of $1.93 per share as on June 24, 2026 at 1:29 am IST.

What is the minimum amount required to buy InflaRx N.V. Stock (IFRX) from India?

Indian investors can start investing in InflaRx N.V. (IFRX) shares with as little as ₹94.735 or $1 (as of June 24, 2026 at 3:39 am IST) using the INDmoney app.
For example: If you want to invest $10 or ₹947.35 in InflaRx N.V. stock (as per the Rupee-Dollar exchange rate as on June 24, 2026 at 3:39 am IST). Based on InflaRx N.V. share’s latest price of $1.93 as on June 24, 2026 at 1:29 am IST, you will get 5.1813 shares of InflaRx N.V.. Learn more about fractional shares .

What are the returns that InflaRx N.V. has given to Indian investors in the last 5 years?

InflaRx N.V. stock has given -36.67% share price returns and 27.69% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?